Five-year Results of the PERLE Implant in Breast Augmentation and Augmentation-mastopexy

Advances in the manufacturing of breast implants through improved shell architecture, gel cohesivity, and surface topography may mitigate against post-operative complications following breast augmentation.

The present study aims to report five-year results of the PERLE implant (GC Aesthetics) which is a round breast implant with an average surface roughness of 5 μm that was launched in 2020.

A retrospective cohort study was performed including consecutive patients undergoing primary or secondary bilateral breast augmentation and augmentation-mastopexy with PERLE implants between December 2020-2025. The primary outcomes were implant-related complications and re-operation over five years. Outcomes were analysed per-patient and per-implant.

738 patients (augmentation, n=592; augmentation-mastopexy, n=146) receiving 1,476 implants were followed up for up to five years (median follow-up, 34 months). Implant-related complications occurred in 2.8% of patients overall: 2.2% (13/592) following augmentation and 5.5% (8/146) following augmentation-mastopexy. The per-patient rate of capsular contracture was 0.5% following augmentation (n=3) and 0.7% following augmentation-mastopexy (n=1). Per-implant, the overall rate of capsular contracture was 0.3% (subglandular, 0.4% [2/476]; dual-plane, 0.3% [2/690]; subfascial, 0.0% [0/296]; and submuscular, 0.0% [0/14]). The rate of implant malposition was 0.7% and 1.4% per implant inserted, following augmentation and augmentation-mastopexy, respectively. The 1-, 3- and 5-year re-operation rate for implant-related complications was 1.2%, 2.1% and 2.5%, respectively in the augmentation group. No cases of implant rupture, rippling or BIA-ALCL were reported.

At five years, breast augmentation and augmentation-mastopexy using the PERLE implant demonstrated low rates of capsular contracture, implant malposition, and implant-related re-operation.